Pages that link to "Q40471168"
Jump to navigation
Jump to search
The following pages link to Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor. (Q40471168):
Displaying 21 items.
- Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer (Q38674886) (← links)
- Targeting cancer-related inflammation in the era of immunotherapy (Q39044981) (← links)
- Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40 monocyte differentiation (Q39454807) (← links)
- Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma (Q42362520) (← links)
- Targeting immunosuppressive adenosine in cancer (Q46140918) (← links)
- Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications (Q47325431) (← links)
- De-novo and acquired resistance to immune checkpoint targeting. (Q47326952) (← links)
- Macrophages and CD8 T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors. (Q52691698) (← links)
- IL-12 Gene Electrotransfer Triggers a Change in Immune Response within Mouse Tumors (Q60907692) (← links)
- Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (Q64112827) (← links)
- The Immune Revolution: A Case for Priming, Not Checkpoint (Q88318271) (← links)
- Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity (Q90660461) (← links)
- Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies (Q91151465) (← links)
- Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future (Q91950939) (← links)
- Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features (Q92173942) (← links)
- Rational combinations of immunotherapy with radiotherapy in ovarian cancer (Q92306380) (← links)
- Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy (Q92334728) (← links)
- Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion (Q92538625) (← links)
- Concepts for agonistic targeting of CD40 in immuno-oncology (Q92559568) (← links)
- Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors (Q98466646) (← links)
- Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies (Q98735502) (← links)